Full-Time

Key Account Director

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$140k - $210kAnnually

+ Incentive Compensation + Restricted Stock Units

Expert

Company Historically Provides H1B Sponsorship

Remote in USA

Remote roles are open to individuals in unincorporated Los Angeles.

Category
Lab & Research
Life Sciences
Required Skills
Sales

You match the following Tempus's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Minimum 10+ years in Business Development and Sales in the Life Sciences sector as lead account and relationship manager (Pharma / Biotech)
  • 5+ years working with companies who serviced Life Sciences companies in Research & Development and/or Real World Data
  • Proven experience delivering consistent sales results within Biopharma accounts
  • Entrepreneurial sales approach; thrives most in a high growth, rapidly evolving business environment
  • Expert in influencing internal and external stakeholders to quickly solve problems and deliver results
  • Deep understanding of the drug development life cycle and has relationships with key Biopharma industry stakeholders
  • Proven ability to navigate multi-faceted client organizations with repeated success
  • Exceptional account management and strategic selling skills, articulation of issues and an ability to navigate a wide range of stakeholders to solve problems
  • Proven track record of establishing credibility as a trusted advisor with clients
  • Experience negotiating and closing large and complex multi-year deals
  • Strong understanding of molecular data and artificial intelligence in drug discovery
  • Bachelor degree in a Science or Business discipline; Advanced degree (MBA, PhD or Healthcare certification) desired
Responsibilities
  • Proactively identify and close new sales opportunities within designated biopharma account(s).
  • Meet and exceed bookings goals while delivering on established strategic objectives for specific customer accounts
  • Develop a deep understanding of each account's unique needs and challenges and create a supporting Tempus strategy to address
  • Develop and drive global account strategy in coordination with our scientific and business operations teams
  • Build and maintain executive relationships & drive an executive engagement plan utilizing Tempus senior leadership team.
  • Become an expert in the partner’s strategy, pipeline and portfolio to proactively determine all areas that the Tempus platform could be leveraged for advancing innovation
  • Negotiate, secure and manage pull-through of contracts with assigned client accounts
  • Lead a cross functional team of Product Specialists, Alliance Managers, Translational Researchers and Commercial Operations to deliver value for our customers.
  • Partner with our customers to develop impactful case studies leveraging the Tempus platform to advance precision medicine
  • Contribute to the development of the Life Sciences portfolio by providing feedback to Leadership regarding client responses and suggestions; maintain a solution-oriented mindset
  • Track progress against defined strategic objectives and revenue goals; review progress/setbacks frequently with broader Account Team and Tempus Leadership
  • Travel approximately 40% of working time, domestically and internationally
Desired Qualifications
  • Advanced degree (MBA, PhD or Healthcare certification) desired

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • AI integration in EHR systems supports Tempus' data analytics capabilities.
  • Growing demand for personalized medicine boosts Tempus' therapy solutions.
  • AI-powered health apps market growth supports Tempus' olivia app success.

What critics are saying

  • Ambry Genetics acquisition may strain Tempus' financial resources and integration efforts.
  • xT CDx test faces competition, impacting market penetration and revenue.
  • olivia app may raise privacy concerns, affecting user adoption and trust.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform offers personalized therapy options, enhancing patient care and drug development.
  • Tempus' pan-cancer organoid platform and liquid biopsy assay are unique in cancer research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Hit Consultant
Jan 23rd, 2025
Tempus Ai Launches Ai-Powered Personal Health Concierge App

What You Should Know:– Tempus AI, a provider of AI-powered precision medicine launches olivia, an innovative personal health concierge app designed to revolutionize how patients manage their health information.– olivia brings together a patient’s health data from various sources, leverages AI to provide actionable insights, and empowers patients to take control of their health journey.Centralizing Health DataOlivia serves as a central hub for all of a patient’s health information. Patients can connect to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. This comprehensive data integration allows patients to access a complete and accurate picture of their health history.Actionable Insights Through AIolivia’s AI-enabled capabilities transform raw data into actionable insights. Patients can ask questions about their records, summarize their health information, and receive personalized responses based on their data. For example, a patient can ask, “Summarize my health status,” and olivia will provide a clear, concise summary of their health information.Empowering Patients to Take Control of Their HealthIn addition to centralizing data and providing actionable insights, olivia offers several other features to enhance the patient experience:Smart Profile Summary: olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team.olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team. AI-enabled Notetaker: olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface.olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface

OncLive
Jan 15th, 2025
NGS-Based xT CDx Test Is Now Commercially Available in United States for Solid Tumor Profiling

Tempus announces the national launch of FDA-approved xT CDx test.

BioPharmaTrend
Jan 8th, 2025
Tempus and Genialis Partner on RNA-Based Biomarker Algorithms

Tempus AI has partnered with Genialis to develop RNA-based biomarker algorithms aimed at improving cancer diagnostics and treatment outcomes.

HR Tech Wire
Jan 8th, 2025
Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company.

MedTech Dive
Jan 8th, 2025
Beta Bionics files for IPO, $44.7M revenue

Beta Bionics, maker of the iLet Bionic Pancreas, filed for an IPO to be listed on Nasdaq as "BBNX." The company aims to use the proceeds to expand sales, manufacturing, and develop new features. In 2024, Beta Bionics reported $44.7 million in revenue and a net loss of $36.6 million for the first nine months. The iLet pump, cleared by the FDA in 2023, is designed for Type 1 diabetes patients and requires less user input. The company plans to expand its use for Type 2 diabetes and develop a patch pump version.

Stock Titan
Jan 7th, 2025
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference

Tempus to present at 43rd Annual J.P. Morgan Healthcare Conference.

MarketBeat
Dec 13th, 2024
Tidal Investments LLC Makes New $7.63 Million Investment in Tempus AI, Inc. (NASDAQ:TEM)

Tidal Investments LLC makes new $7.63 million investment in Tempus AI, Inc. (NASDAQ:TEM).

Stock Titan
Nov 12th, 2024
Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR(R)

Tempus announced a collaboration with Flatiron Health to integrate its genomic testing capabilities into Flatiron's OncoEMR(R) platform through Molecular Profiling Integration (MPI).

Orange County Business Journal
Nov 11th, 2024
Tempus AI to Buy Ambry Genetics for $600M - Orange County Business Journal

Orange County’s third largest medical diagnostics and testing company is being acquired by a fast-growing Chicago-based firm using artificial intelligence for precision medicine.Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

OncLive
Nov 7th, 2024
Immune Profile Score Algorithmic Test Is Now Available to Help Inform Checkpoint Inhibitor Use in Cancer

Tempus announces the clinical launch of its Immune Profile Score algorithmic test.

Business Wire
Oct 28th, 2024
Tempus Announces Collaboration With JW Pharmaceutical to Apply Real-World Data and Biological Modeling to Enhance Early Research and Development

Tempus announces collaboration with JW Pharmaceutical to apply real-world data and biological modeling to enhance early research and development.